任峰2024VBEF演讲：生成式人工智能和机器人技术赋能药物研发（药企数字化研发论坛）.pdf

FromGenerativeAItoClinic:

End-to-EndDrugDiscoveryand

DevelopmentDrivenbyAI

FengRen,PhD

Co-CEOCSO

1

InsilicoMedicineRestricted(Level3)

2

InsilicoMedicineRestricted(Level3)

TraditionalDrugRDTakes10Yearsand$2B*

Fromthediscoverytothelaunchofanewdrug

DiseaseHypothesis

and

TargetDiscovery**

LeadSubmission

Target-to-hitHit-to-leadPreclinicalPhaseIPhaseIIPhaseIII

optimizationtolaunch

Usuallytakesfrommonths

todecades,performed

inacademicinstitutions

usinggovernmentfundsDevelopmentcostin2010

$1.8B(aftertargetdiscovery)

1-5%80%75%